Detalles de la búsqueda
1.
A multifactorial screening strategy to identify anti-idiotypic reagents for bioanalytical support of antibody therapeutics.
Anal Biochem
; 470: 52-60, 2015 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25447458
2.
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Nat Metab
; 6(2): 290-303, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38316982
3.
Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities.
Anal Chem
; 85(5): 2731-8, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23373459
4.
FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.
J Biol Chem
; 285(8): 5165-70, 2010 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-20018895
5.
Discovery of Selective Pituitary Adenylate Cyclase 1 Receptor (PAC1R) Antagonist Peptides Potent in a Maxadilan/PACAP38-Induced Increase in Blood Flow Pharmacodynamic Model.
J Med Chem
; 64(6): 3427-3438, 2021 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33715378
6.
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.
Cell Rep Med
; 2(5): 100263, 2021 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34095876
7.
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism.
Nat Commun
; 11(1): 4981, 2020 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33020469
8.
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Am J Physiol Endocrinol Metab
; 297(5): E1105-14, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19706786
9.
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Sci Transl Med
; 10(472)2018 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30567927
10.
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward ß-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
Endocrinology
; 158(5): 1314-1327, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28324011
11.
Implementation of a universal analytical method in early-stage development of human antibody therapeutics: application to pharmacokinetic assessment for candidate selection.
Bioanalysis
; 4(19): 2357-65, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23088462
12.
Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
Endocrinology
; 153(1): 69-80, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22067317
13.
Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
Endocrinology
; 153(9): 4192-203, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22798348
14.
Treating diabetes and obesity with an FGF21-mimetic antibody activating the ßKlotho/FGFR1c receptor complex.
Sci Transl Med
; 4(162): 162ra153, 2012 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23197570
15.
Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
PLoS One
; 7(11): e49345, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23209571
Resultados
1 -
15
de 15
1
Próxima >
>>